Vicebio Secures $100 Million in Series B Funding to Accelerate Development of Cutting-Edge Respiratory Virus Vaccines using Molecular Clamp Technology

We are thrilled to announce that Vicebio has successfully raised $100 million in funding to accelerate the development of its groundbreaking vaccine platform. Vicebio, a pioneering biotech company at the forefront of vaccine innovation, harnesses the power of molecular clamp technology to create highly effective vaccines against life-threatening respiratory viruses. This cutting-edge approach enables the stabilization of viral envelope glycoproteins, allowing for the formulation of multivalent single-shot vaccines that provide robust protection against multiple strains of respiratory viruses. With this new funding, Vicebio aims to broaden its research capabilities, further optimize its vaccine formulations, and expedite clinical trials to bring these life-saving vaccines to market faster. Our dedicated team is committed to addressing the urgent demand for effective respiratory virus solutions, especially in the face of emerging and re-emerging viral threats. The investment will also support enhancements in our manufacturing processes and the establishment of strategic partnerships that will allow us to scale production and distribution efforts globally. We believe that with this financial backing, Vicebio is well-positioned to make a significant impact on public health and to protect communities worldwide from the devastating effects of respiratory viruses. We are grateful for the support of our investors, who share our vision of a healthier future, and we look forward to sharing exciting updates on our progress as we work towards our mission of providing innovative vaccine solutions.